The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
暂无分享，去创建一个
T. Pitts | J. Arcaroli | W. Messersmith | E. Cadogan | Aaron Smith | A. Nguyen | K. Quackenbush | S. Bagby | S. Eckhardt | G. Hughes | P. Blatchford | Kalpana M. Devaraj | A. Schreiber | Gemma N. Jones | WM. Tai | Justin Greene | Kevin S. Quackenbush | Patrick J Blatchford